Beneficial effect of lamivudine for hepatitis B transplant recipients
David Mutimer – 30 December 2003
Vertical portal vein clamping in right hepatic lobectomy for live donation or neoplasm
Katsuhiko Yanaga, Yukio Kamohara, Mitsuhisa Takatsuki, Junichiro Furui, Takashi Kanematsu – 30 December 2003 – A modified technique is described in clamping the right branch of the portal vein in right hepatic lobectomy for live donation or neoplasm that allows flush division of the origin of the right branch without causing portal vein stenosis.
Recurrent portal hypertension after composite liver/small bowel transplantation
Thomas M. Fishbein, Sander Florman, Gabriel Gondolesi, Neal S. LeLeiko, Harold A. Mitty, Allan Tschernia, Stuart S. Kaufman – 30 December 2003 – Late technical complications of composite liver/small bowel transplantation procedures are often complex and have not been well defined. Here we describe the unusual presentation and management of two cases of recurrent thrombocytopenia due to hypersplenism resulting from portacaval shunt stenosis. Both patients presented with portal hypertension late after composite liver/small bowel transplantation.
Reduced use of intensive care after liver transplantation: Influence of early extubation
M. Susan Mandell, Dennis Lezotte, Igal Kam, Stacy Zamudio – 30 December 2003 – Postoperative ventilation and admission to the intensive care unit (ICU) is the standard of care in liver transplantation and comprises a significant proportion of transplantation costs. Because immediate postoperative extubation has been reported previously in a selected group of liver transplant recipients, we questioned whether this protocol could be extended to a larger group of patients.
Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation
Raghavakaimal Sreekumar, Deborah L. Rasmussen, Russell H. Wiesner, Michael R. Charlton – 30 December 2003 – Treatment of acute cellular rejection (ACR) is associated with increased viral load, more severe histologic recurrence, and diminished patient and graft survival after liver transplantation for hepatitis C virus (HCV). Recurrence of HCV may be difficult to distinguish histologically from ACR .
Methadone is a medication, not an addiction
Monika Koch, Peter Banys – 30 December 2003
Living donor in urgent cases: Ethical hazard?
Ignazio R. Marino, Howard R. Doyle – 30 December 2003
Safety of right lobectomy in living donor liver transplantation
Kyung‐Suk Suh, Seong Hoon Kim, Sang Beom Kim, Hyuk‐Joon Lee, Kuhn Uk Lee – 30 December 2003 – The goal of this study was to examine the safety and effectiveness of right lobectomy in living donor liver transplantation (LDLT). From January 1999 to January 2002, 100 cases of LDLT were performed at Seoul National University Hospital; 45 involved right lobectomy (RL), 17 involved extended left lobectomy (ELL), 37 involved left lateral segmentectomy (LLS), and 1 involved right posterior segmentectomy. The outcome of RL was compared with those of other types of hepatectomy.
Renal failure late after liver transplantation
James Neuberger – 30 December 2003
Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection
Ashok B. Jain, Bijan Eghtesad, Raman Venkataramanan, Paulo A. Fontes, Randeep Kashyap, Igor Dvorchik, A. Obaid Shakil, Leah Kingery, John J. Fung – 30 December 2003 – Hepatitis C virus (HCV) is currently the most common etiology for liver transplantation (LTx) in the United States. A significant number of patients develop recurrent HCV after LTx. Although there is no completely satisfactory treatment for recurrent HCV, a combination of interferon‐α (INF) and ribavirin remains the most widely used.